A randomized phase II study of gemcitabine versus reduced-dose combination chemotherapy in fragile patients with non-resectable pancreatic cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514291-41-00

Acronym

2024-514291-41-00

Enrollment

Registered

2024-09-10

Start date

2023-10-20

Completion date

Unknown

Last updated

2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Brief summary

Progression Free Survival (PFS)

Detailed description

Overall Survival (OS), Response rate, Number of hospitalizations during treatment, Quality of life assessed by EORTC QLQ-C30 at baseline and after 8, 16, and 24weeks, Cumulative worst toxicity during treatment (Adverse events ≥ grade 3 according to CTCAE version 5.0)

Interventions

DRUGGemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui

DRUGAbraxane 5 mg/ml powder for dispersion for infusion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS)	—

Secondary

Measure	Time frame
Overall Survival (OS), Response rate, Number of hospitalizations during treatment, Quality of life assessed by EORTC QLQ-C30 at baseline and after 8, 16, and 24weeks, Cumulative worst toxicity during treatment (Adverse events ≥ grade 3 according to CTCAE version 5.0)	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026